University of Notre Dame du Lac’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

University of Notre Dame du Lac’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,913	Closed	-$916K	–	57
2020 Q1	$916K	Buy	11,913 +2,650	+29%	+$238K	0.28%	44
2019 Q4	$1.19M	Sell	9,263 -615	-6%	-$59.3K	0.38%	36
2019 Q3	$770K	Sell	9,878 -42,597	-81%	-$4M	0.23%	51
2019 Q2	$5.41M	Buy	+52,475	New	+$4.09M	1.23%	36
2018 Q4	–	Sell	-47,630	Closed	-$2.24M	–	85
2018 Q3	$2.24M	Buy	+47,630	New	+$2.65M	0.42%	67

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

University of Notre Dame du Lac's MRTX Position: Q2 2020 in Review

University of Notre Dame du Lac sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2020, closing a stake of 11,913 shares — an estimated $916K sold.

University of Notre Dame du Lac first reported a position in MRTX in Q3 2018 and held it in 5 quarters. The position peaked at $5.41M in Q2 2019. 200 funds tracked by Wall St. Rank hold MRTX as of Q2 2020.

University of Notre Dame du Lac reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
University of Notre Dame du Lac sold 11,913 Mirati Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $916K.
University of Notre Dame du Lac first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
University of Notre Dame du Lac's Mirati Therapeutics, Inc. Common Stock position peaked at $5.41M in Q2 2019.
200 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2020.

Based on University of Notre Dame du Lac's 13F filing for Q2 2020, filed 14 Aug 2020.